Cargando…
Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign
Recently, the World Health Organization (WHO) approved RTS, S/AS01 (RTS, S) as the world's first malaria vaccine for partial malaria protection in young children at risk. While this immunization drive begins during the unprecedented pandemic of the SARS-CoV-2 Virus, the WHO has also approved 7...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212924/ https://www.ncbi.nlm.nih.gov/pubmed/35757307 http://dx.doi.org/10.1016/j.amsu.2022.104011 |
_version_ | 1784730721817985024 |
---|---|
author | Shah, Pritik A. Hasan, Mohammad Mehedi Sahito, Abdul Moiz Patel, Suyog Y. Ramproshad, Sarker Mondal, Banani Essar, Mohammad Yasir |
author_facet | Shah, Pritik A. Hasan, Mohammad Mehedi Sahito, Abdul Moiz Patel, Suyog Y. Ramproshad, Sarker Mondal, Banani Essar, Mohammad Yasir |
author_sort | Shah, Pritik A. |
collection | PubMed |
description | Recently, the World Health Organization (WHO) approved RTS, S/AS01 (RTS, S) as the world's first malaria vaccine for partial malaria protection in young children at risk. While this immunization drive begins during the unprecedented pandemic of the SARS-CoV-2 Virus, the WHO has also approved 7 Vaccines in 2021 for the vaccination of children at risk. This article explores the quandary that would occur to the officials in charge of carrying out large vaccination campaigns against these two deadly infectious illnesses in several regions including the continent of Africa. The article also outlines the priorities for resolving this dilemma, offers evidence-based solutions, and provides a summary of recent significant events and their consequences. While providing the latest data, a discussion on the causation of the dilemma with clear recommendations for possible solutions has been explored as well. |
format | Online Article Text |
id | pubmed-9212924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92129242022-06-22 Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign Shah, Pritik A. Hasan, Mohammad Mehedi Sahito, Abdul Moiz Patel, Suyog Y. Ramproshad, Sarker Mondal, Banani Essar, Mohammad Yasir Ann Med Surg (Lond) Short Communication Recently, the World Health Organization (WHO) approved RTS, S/AS01 (RTS, S) as the world's first malaria vaccine for partial malaria protection in young children at risk. While this immunization drive begins during the unprecedented pandemic of the SARS-CoV-2 Virus, the WHO has also approved 7 Vaccines in 2021 for the vaccination of children at risk. This article explores the quandary that would occur to the officials in charge of carrying out large vaccination campaigns against these two deadly infectious illnesses in several regions including the continent of Africa. The article also outlines the priorities for resolving this dilemma, offers evidence-based solutions, and provides a summary of recent significant events and their consequences. While providing the latest data, a discussion on the causation of the dilemma with clear recommendations for possible solutions has been explored as well. Elsevier 2022-06-18 /pmc/articles/PMC9212924/ /pubmed/35757307 http://dx.doi.org/10.1016/j.amsu.2022.104011 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Short Communication Shah, Pritik A. Hasan, Mohammad Mehedi Sahito, Abdul Moiz Patel, Suyog Y. Ramproshad, Sarker Mondal, Banani Essar, Mohammad Yasir Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign |
title | Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign |
title_full | Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign |
title_fullStr | Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign |
title_full_unstemmed | Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign |
title_short | Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign |
title_sort | vaccine dilemma for children at risk: recently approved malaria vaccine versus ongoing covid-19 vaccination campaign |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212924/ https://www.ncbi.nlm.nih.gov/pubmed/35757307 http://dx.doi.org/10.1016/j.amsu.2022.104011 |
work_keys_str_mv | AT shahpritika vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign AT hasanmohammadmehedi vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign AT sahitoabdulmoiz vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign AT patelsuyogy vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign AT ramproshadsarker vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign AT mondalbanani vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign AT essarmohammadyasir vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign |